Podcasts about Aid

Farm Aid is heading to Virginia Beach for the first time Saturday, Sept. 26, and global demand for crop protection products will continue growing as farmers work to protect yields and meet rising food demand.

This episode follows a wide-ranging panel convened at Stanford's King Center on Global Development, featuring Gyude Moore, as well as Gates Foundation CEO Mark Suzman, former USAID Administrator and Ambassador Mark Green, and Chair and Founder of the Liquidity and Sustainability Facility Vera Songwe - The future of global development: Approaches and partnerships for a new reality.Bilateral aid to sub-Saharan Africa will fall by between 16% and 28% this year, according to the IMF. In past downturns, multilateral and humanitarian funding tended to fill the gap when bilateral aid dropped. This time those channels are shrinking too.Gyude Moore, who ran the Liberian President's Delivery Unit under Ellen Johnson Sirleaf, thinks the contraction is structural rather than a passing effect of the Trump administration, and that recipient countries should stop expecting the old arrangement to return. He wants economic growth put at the centre of development rather than treated as one programme among several. Instead of letting donors decide which programmes are run, he says, countries should run a growth diagnostic: a way of identifying the two or three constraints doing most to hold an economy back. Governments can then reorganise their budgets around removing those constraints, and use the diagnostic to decide which offers of aid to take and which to turn down. Moore calls this “sovereignty through analytics”. Aid was meant to be temporary, he argues, and the job now is to quickly reach the point of not needing it.To cite this episode:Phillips, Tim, and W. Gyude Moore. 2026. "The end of aid dependency.” VoxDev Talks (podcast). Assign this as extra listening. The citation above is formatted and ready for a reading list or VLE.About the guestW. Gyude Moore is a distinguished fellow at the Energy for Growth Hub and a non-resident fellow at the Center for Global Development. He was Liberia's minister of public works from December 2014 to January 2018, and before that deputy chief of staff to President Ellen Johnson Sirleaf and head of the President's Delivery Unit, which oversaw more than $1 billion of road, power and port projects in a country rebuilding after civil war. He also lectures at the University of Chicago's Harris School of Public Policy. His work covers African infrastructure, energy, industrial policy and development finance.Cited in this episodeThe scale of the cuts. The IMF's October 2025 Regional Economic Outlook for sub-Saharan Africa, using OECD figures, projects bilateral aid to the region falling by 16% to 28% in 2025, with more cuts likely. Moore says the cuts to multilateral and humanitarian funding run higher again, and that the most aid-dependent countries have been hit hardest, through weaker health, education and nutrition systems.Growth diagnostics. A way of finding the constraints that matter most: the one or two that, once removed, allow others to ease. Moore likens it to a doctor running tests before prescribing. The method is associated with the Growth Lab at Harvard. He suggests governments hire an independent party to run the analysis, so the findings cannot be dismissed as political.The Millennium Challenge Corporation. A US agency that runs what it calls a constraints analysis, then funds the removal of the constraint it finds. Moore offers it as an existing model for diagnostic-led aid, while noting that it has critics.Sovereignty through analytics. Moore's phrase for using a credible diagnostic to set the terms with donors. A government can say what it is trying to do, ask for help where it needs it, and decline what does not fit. He points to Ghana, Zambia and Zimbabwe rejecting or walking away from US health agreements under the America First Global Health Strategy as evidence that recipient governments now have that leverage and are willing to use it.The Development Alliance. Liberia's attempt, around 2014 and 2015, to bring every donor and NGO into one room to map who was doing what, spot duplication and find the sectors nobody was covering. Moore's assessment: useful, but voluntary, not written into law, and not built around a single diagnostic. His conclusion is that such a framework should be put on a legal footing.Five-year plans. Moore, who teaches in China each autumn, points to the discipline that fixed planning periods impose, and argues that legislation can do a similar job of holding a development strategy steady across changes of government.Delivery units. Small teams set up to push complex projects through where the wider bureaucracy cannot. Moore ran one in the Liberian presidency and calls them islands of competence; he offers them as a way around weak implementation.The European politics of aid. Moore's reason for thinking the window may close. Nativist parties are gaining ground across Europe, from the AfD to Reform UK to the PVV in the Netherlands, and an ageing population will pull more public money homeward. Countries that do not adjust, he warns, may find the external funding gone.

Queensryche toi kultakautenaan upean progressiivisen hevimusiikkinsa aiheiksi yhteiskunnallisia kysymyksiä ja ihmismielen syvimpiä virtauksia. Älykkömetallin pioneerit ovat nyt Rock Around The Blogin tarkastelussa, eli Reidar Palmgren ja Sami Ruokangas pohtivat amerikkalaisbändi Queensrychen merkitystä itselleen ja rockmusiikin historialle. Hienon musiikin äärellä mieleen tulee monenlaista muistoa ja ajatusta, munakellosta Joey Tempestin virnistelevään naamaan. Kuuntele, viihdy ja sivisty. Jakson soittolista: https://open.spotify.com/playlist/2seKi2OhKoqpdoSJQ6f5t8?si=5781c5223196439f Meningeissä ovat mukana Led Zeppelin, Deep Purple, Black Sabbath, Dio, Kerrang, Iron Maiden, WASP, Ritchie Blackmore, Adrian Smith, Geoff Tate, Bruce Dickinson, Rob Halford, Ian Gillan, Helloween, Michael Kiske, Andi Deris, Nirvana, Manowar, Twisted Sister, Hear 'n Aid, Judas Priest, Motörhead, Jimi Hendrix, Dream Theater, Chris DeGarmo, Marmorivideo, Ronnie James Dio, Anne Rice, Brad Pitt, Tom Cruise, Type O Negative, Popeda, KISS, Duran Duran, Yes, Genesis, Europe, Bon Jovi, Blue Öyster Cult, Black Sabbath, Scott Rockenfield, Michael Wilton ja Eddie Jackson. Seuraa meitä somessa ja anna palautetta: www.facebook.com/RockAroundTheBlogFinland www.instagram.com/samiruokangas

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform. To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.References1: Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Ketan Dhatariya, MD, PhD, MS, consultant physician at Norfolk and Norwich University Hospitals, to discuss the evolving landscape of diabetes care, technology access, and clinical implementation. To begin the episode, Dhatariya shares his perspective on the challenges facing diabetologists, including workforce pressures, specialist training, and the difficulty of translating rapidly expanding diabetes guidelines and innovations into everyday clinical practice. The conversation then shifts to the differences between healthcare systems and how those structures influence access to diabetes therapies. Dhatariya discusses the UK's publicly funded healthcare model and the ongoing challenge of balancing the cost of emerging medications and technologies with their long-term benefits. He highlights the importance of demonstrating that investments in diabetes care today can reduce complications and healthcare costs in the future.Dhatariya then reviews the progress of continuous glucose monitoring (CGM) and automated insulin delivery (AID) adoption in the UK. He explains that CGM use among people with type 1 diabetes has become widespread, particularly among children, and that access to closed-loop systems continues to expand through structured implementation plans. He emphasizes the meaningful improvements these technologies have provided, including better glycemic outcomes among children and pregnant individuals, who may experience significant benefits from improved glucose management.The discussion explores how diabetes technology can support people with different lifestyles and challenges, while challenging assumptions about which patients may benefit most from advanced therapies. Dhatariya highlights that CGM and AID can provide valuable support for individuals who may struggle with traditional insulin management, while also emphasizing the need for appropriate education and follow-up to ensure safe and effective use.The group also discusses CGM use in type 2 diabetes and the growing evidence supporting broader access. Dhatariya explains that adoption has been slower because of the larger population affected by type 2 diabetes but notes emerging data suggesting CGM may help reduce complications, hospitalizations, and long-term healthcare costs. He describes the impact of seeing real-time glucose data, explaining how personal experience with CGM can help people better understand the relationship between food, behavior, and glucose patterns.The conversation then turns to access to GLP-1 receptor agonists in the UK and how healthcare systems determine eligibility for newer therapies. Dhatariya discusses the role of national guidance and health economic evaluations in balancing access, affordability, and sustainability. He highlights how improving obesity-related disease management may have broader benefits, including helping reduce the burden of diabetes, cardiovascular disease, and other chronic conditions.The episode also explores inpatient diabetes care and the increasing presence of diabetes technology in hospital settings. Dhatariya discusses guidance developed by the Joint British Diabetes Societies for Inpatient Care to help clinicians safely manage patients admitted while using CGM, insulin pumps, and AID systems. He emphasizes that devices should not automatically be removed and that patients may be able to continue using technology when they are well enough and capable of managing their systems.Finally, Dhatariya discusses the importance of structured diabetes education, including the DAFNE (Dose Adjustment For Normal Eating) program, which teaches carbohydrate counting, insulin adjustment, and self-management skills. He emphasizes that as diabetes technology becomes more advanced, education remains essential for both patients and clinicians. The episode concludes with a discussion of the need for continued advocacy, specialist care, and equitable access to ensure people with diabetes can benefit from ongoing advances in diabetes technology.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Dhatariya reports disclosures with AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.

California's End of Life Option Act, which allows people with certain terminal illnesses and a life expectancy of less than six months to receive medication that ends their life, turns 10 this month. Yet despite polling showing the policy is popular, access remains complicated and controversial, and few eligible patients actually pursue the option. We'll discuss how the program has worked in California and examine the shifting national support for medical aid-in-dying policies. Guests: Paula Span, adjunct professor, Columbia University Graduate School of Journalism; writes the New Old Age column, a co-production of The New York Times and KFF Health News Dr. Lonny Shavelson, physician and director of education, Academy of Aid-in-Dying Medicine; medical doctor who's provided aid-in-dying care for 7 years Learn more about your ad choices. Visit megaphone.fm/adchoices

Election Results From Yesterday's Primaries With a Focus on California | Trump's Roy Cohn Does a Bait and Switch Ending the $1.8 Billion Slush Fund While Shielding Trump and His Family From IRS Audits | Trump Publicly Displays Anger at Netanyahu While Quietly the Pentagon Takes Over Oversight of Aid to Israel

Balazs Nemethi, CEO of the Agent Community, explains why AI agents need identities and why the window to decide who controls that infrastructure is closing fast. He breaks down how a community-governed effort is working to secure .agent as a top-level domain, and why domains are a smart foundation for agent identity. Key Takeaways: Why agents need identities, including personalized names and domains What challenges will emerge around trust, safety, and accountability as agents scale, and why domains are a powerful trust layer What community governance could change by preventing single-company control over agent identity How the ICANN application process works, and the one bylaw that gives community a real shot at winning a TLD Why verifying agents (not just humans) may be the smarter approach to trust on the agentic web Guest Bio: Balázs Nemethi is a Hungarian technologist and entrepreneur working at the intersection of internet infrastructure, identity, and AI. He is the founder of the Agent Community at agentcommunity.org, a community-backed effort to establish .agent as a new top-level domain and identity layer for AI agents. He is also the author of AID, a DNS-first standard for agent identity and discovery. Previously, he helped scale the Decentralized Identity Foundation to more than 300 organizations; founded Taqanu, a financial-inclusion company serving refugees in Germany; and built Web3 compliance infrastructure at Veri Labs, where he is the inventor on a U.S. patent for programmable assets. ---------------------------------------------------------------------------------------- About this Show: The Brave Technologist is here to shed light on the opportunities and challenges of emerging tech. To make it digestible, less scary, and more approachable for all! Join us as we embark on a mission to demystify artificial intelligence, challenge the status quo, and empower everyday people to embrace the digital revolution. Whether you're a tech enthusiast, a curious mind, or an industry professional, this podcast invites you to join the conversation and explore the future of AI together. The Brave Technologist Podcast is hosted by Luke Mulks, VP Business Operations at Brave Software—makers of the privacy-respecting Brave browser and Search engine, and now powering AI everywhere with the Brave Search API. Music by: Ari Dvorin Produced by: Sam Laliberte  

Aid to farmers devastated by hurricanes and freeze, with Florida 3rd US House Rep. Kat Cammack. Defending her opposition to the weaponization fund, the changing GOP tide in California, and finding the right end in Iran.

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

In Northwest Syria, a critical network of hospitals faces a unique challenge: how do you pay medical staff and fund healthcare when your country is completely cut off from the global financial system?Due to economic sanctions and a fractured banking infrastructure following over a decade of civil war, humanitarian organizations like the Union of Medical Care and Relief Organizations (UOSSM) have struggled to safely distribute funds.Previously, hospital employees had to embark on grueling, risky journeys to the Turkish border, waiting in long lines for hours just to collect their salaries in physical cash.In this episode, we take a firsthand look at how the evolution of cross-border payments is impacting real lives on the ground.UOSSM is sending bulk payments to its employees on the blockchain, who receive their salaries in their digital wallets, and then use informal Hawala networks to off-ramp the digital dollars into cash. In this episode of Money Trails, presented by‪ Stellar Development Foundation‬ we're joined by Ibrahim Abdulhuseyin, CEO & Co-founder & CEO of DigiBank, Tori Samples, the Director of Product, Stellar, and Younes Al-Haj Saleh, from UOSSM's Financial Operations.Watch the full episode on YouTube.00:00 - Intro01:27 - How employees used to get paid02:38 - Civil war and sanctions03:47 - UOSSM's payment struggles05:58 - Stablecoin payments06:49 - How Digibank built Syria's cash-out network08:38 - Bulk payments with SDP10:30 - Aid orgs are crypto adoptersOur Links -

Aid is ramping up to the Democratic Republic of Congo, and vaccine work is progressing. But what the Ebola response most lacks is trust of the community. European governments and businesses are wary of their dependence on America's tech giants; we examine a spate of home-grown efforts. And sticky toffee pudding, a staid British classic, gets a sweet social-media boost. Guests and host:John McDermott, chief Africa correspondentChristian Odendahl, European economics editorỌrẹ Ogunbiyi, Africa correspondent and sticky toffee pudding enthusiastJason Palmer, co-host of “The Intelligence”Topics covered: Ebola outbreak, Democratic Republic of Congo, epidemiology, vaccinesEuropean technology, American tech giants, technological sovereignty sticky toffee puddingGet a world of insights by subscribing to Economist Podcasts+. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Aid is ramping up to the Democratic Republic of Congo, and vaccine work is progressing. But what the Ebola response most lacks is trust of the community. European governments and businesses are wary of their dependence on America's tech giants; we examine a spate of home-grown efforts. And sticky toffee pudding, a staid British classic, gets a sweet social-media boost. Guests and host:John McDermott, chief Africa correspondentChristian Odendahl, European economics editorỌrẹ Ogunbiyi, Africa correspondent and sticky toffee pudding enthusiastJason Palmer, co-host of “The Intelligence”Topics covered: Ebola outbreak, Democratic Republic of Congo, epidemiology, vaccinesEuropean technology, American tech giants, technological sovereignty sticky toffee puddingGet a world of insights by subscribing to Economist Podcasts+. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

574,623 views  Streamed live on May 25, 2026  #TCC #Shelest #Front#Arestovych #Shelest #War #Belarus #LukashenkoFundraising for a vehicle to support the logistics needs of the 5th Company, 420th Separate Battalion of Unmanned Systems (OBBpS).

Cenk Uygur has been banned from the UK for criticizing Israel. He cannot attend SXSW London to give a speech at Oxford. Travel restrictions based on what you say about Israel.The Empire is really showing its hand. This is the flaw in the system. How do these Jewish supremacist have so much power? They can behave this way and openly shoot rape and torture children because western governments are based on money. They have unlimited lobbying power because the first thing they lobby for is more foriegn aid and they recycle a portion of that money back on more lobbying. You might have to click through to see the video on Twitter. Please share it we cracked 3.6 Million but it needs to be 10 million. You can support us and get the word out with this End all Aid to Israel gear. Remember don't put the magnets on busses that's illegal. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.ryandawson.org/subscribe

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent FDA approval of MannKind's inhaled insulin Afrezza for pediatric patients aged 6 years and older with both type 1 and type 2 diabetes, describing the decision as a major milestone in diabetes therapeutics and the first expansion of the therapy beyond adults. The episode centers on the clinical implications of the approval, the pharmacologic advantages of inhaled insulin, and the practical considerations surrounding implementation in pediatric care settings.The hosts review findings from the INHALE-1 trial, which enrolled 230 pediatric participants aged 4 to 17 years and compared inhaled insulin used alongside basal insulin with standard multiple daily injection (MDI) therapy over 56 weeks. Bellini emphasizes that the study achieved its primary objective of demonstrating glycemic outcomes comparable to traditional insulin regimens, noting that insulin studies are generally designed to establish equivalence rather than superiority. Beyond similar glycemic control, the hosts highlight several clinically meaningful secondary observations, including stable BMI among participants receiving inhaled insulin compared with weight gain in the MDI cohort, increased treatment satisfaction reported by both adolescents and parents of younger children, comparable hypoglycemia rates, and the absence of new safety concerns. Bellini also notes that no decline in lung function was observed among participants using inhaled insulin, despite historical concerns surrounding pulmonary safety with inhaled therapies.A major focus of the discussion is the physiologic pharmacokinetic profile of Afrezza, which Isaacs characterizes as the most physiologic insulin currently available. She explains that inhaled insulin demonstrates measurable activity within approximately 12 minutes, peaks within 35 to 45 minutes, and clears the bloodstream in roughly 90 minutes. The hosts contrast this with subcutaneous rapid-acting insulin analogs, including ultra-rapid formulations, which retain a prolonged “tail” of insulin activity that can increase hypoglycemia risk. Isaacs and Bellini suggest that the shorter duration of inhaled insulin may reduce the cycle of overtreating hypoglycemia and subsequent rebound hyperglycemia, thereby potentially contributing to the absence of weight gain observed in the trial. Bellini further emphasizes that the rapid onset and offset of inhaled insulin restore some of the flexibility and spontaneity often lost in intensive insulin therapy, particularly around meal dosing and correction strategies.The conversation also situates inhaled insulin within the broader framework of individualized diabetes management and the ADA Standards of Care. Isaacs stresses that the approval should not be viewed as competing with automated insulin delivery (AID) systems, but rather as expanding patient choice. The hosts discuss how inhaled insulin may be especially valuable for individuals who do not wish to wear insulin pumps, desire periodic breaks from technology, or want to reduce the burden of injections. Isaacs additionally highlights the growing prevalence of pediatric type 2 diabetes and notes that, despite advances in incretin-based therapies, many youth still require insulin therapy. In that context, the possibility of pairing inhaled mealtime insulin with emerging once-weekly basal insulin formulations and GLP-1 receptor agonists is presented as a potentially transformative strategy for minimizing injection burden.Bellini and Isaacs also address practical implementation challenges within school settings. Because inhaled insulin acts rapidly, Bellini notes that administration timing may need to shift from the nurse's office to the cafeteria environment to avoid hypoglycemia if meals are delayed. At the same time, both hosts recognize that the flexibility of postprandial dosing could offer advantages for children with inconsistent eating patterns or concerns about privacy surrounding insulin administration. They further discuss the utility of inhaled insulin for rapid glucose corrections, noting that additional doses can be administered far sooner than with traditional injected rapid-acting insulin.The episode concludes with discussion of anticipated affordability initiatives from MannKind Corporation, including bridge programs designed to improve early access and reduce financial barriers to therapy. Isaacs and Bellini commend the company's efforts to secure pediatric approval and express optimism that broader availability of inhaled insulin will expand individualized treatment options, improve patient satisfaction, and enhance quality of life for children and adolescents living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: HOLDER

Comprehensive coverage of the day's news with a focus on war and peace; social, environmental and economic justice. Ebola virus Aid flows to Ebola-stricken region, US to divert exposed Americans to Kenya clinic instead of specialized clinics in US; Progressive lawmakers back Steyer for CA governor, as many voters remain suspicious of billionaire candidate's massive campaign spending; Attorney General Bonta sues 23 and Me over data breach of sensitive genetic information; Democrat National Committee leaders discuss state's commitment to rural voters compared to Republicans;  Epstein documents show millionaire sex offender's ties to US military intelligence The post Aid flows to Ebola-stricken region, US to divert exposed Americans to Kenya clinic; Progressive lawmakers back Steyer for governor as many voters remain suspicious of billionaire candidate – May 28, 2026 appeared first on KPFA.

The Trump Administration has made little secret of its desire to dismantle the Federal Emergency Management Agency and give states the responsibility to respond to all manner of natural disasters on their own. FEMA has endured tremendous internal strife over leadership, and reports have suggested its mission has been compromised by partisan decision-making: President Trump—the sole arbiter of who ultimately gets FEMA relief—has rejected aid for Democratic-led states at the highest rate in the agency's history.  This has led to accusations of emergency aid being used as a “political cudgel,” and has had a chilling effect on some of the rank-and-file staff at the agency. The New Yorker Radio Hour's Adam Howard speaks to a longtime employee of FEMA about what's going on behind the scenes, and whether it could have a negative impact on the agency's ability to respond to the next emergency.  The subject of this interview is currently working for FEMA, a federal agency, and he asked to remain anonymous. His voice has been digitally regenerated for the audio of this interview. Further reading and listening:  “American Emergency: The Movement to Kill FEMA,” by “On the Media” “Outrage and Paranoia After Hurricane Helene,” by Jessica Pishko “For the Victims of Florence, Trump Needs to Prove that He Can Get Hurricane Recovery Right,” by Doug Bock Clark and Charles Bethea “Inequality and Hurricane Harvey,” by Ben Taub   New episodes of The New Yorker Radio Hour drop every Tuesday and Friday. Join host David Remnick as he discusses the latest in politics, news, and current events in conversation with political leaders, newsmakers, innovators, New Yorker staff writers, authors, actors, and musicians. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shownotes After the assassination of its leader in September 2024, Hezbollah sank to its weakest point since its founding in 1982. Supporters began to doubt Hezbollah's capabilities, and detractors—inside Lebanon and abroad—planned to dismantle the group. In March of this year, Lebanon's government outlawed Hezbollah's powerful militia. Many of Hezbollah's competitors and critics declared the end of the group's military capability and political base. But Hezbollah's strength has returned. This spring, as Israel has expanded its occupation of southern Lebanon, Hezbollah has fought effectively. It's all looking very much like a comeback. Century International fellow Sima Ghaddar has closely tracked Hezbollah's constituents and power, and shares a granular look at how the group has revived, and how researchers can assess the notoriously opaque organization. Related reading Nathan Brown, “Rubble is Israel's Doctrine, Not a Case of Improvisation,” Carnegie Endowment, May 21, 2026 Sam Heller, “Trump's Lebanon Negotiations Are Breaking the Country,” Foreign Policy, May 15, 2026 Sima Ghaddar, “Doubting the Party, Revering Its Ideology: Hezbollah's Battered Constituencies Reckon with a Year of Loss.”  US Treasury, “Treasury Targets Hizballah-Aligned Officials Obstructing Peace and Disarmament,” May 21, 2026 Mohamad Bazzi, “Is This What War Looks Like Now?” Guardian, April 24, 2026 Participants SIma Ghaddar is a fellow at Century International and a sociologist whose research spans humanitarianism, the politics of international aid, political sociology, and popular mobilization in the Middle East and the Global South. She holds a PhD in Sociology from the University of California, Los Angeles. Her dissertation, “Brokers of the Humanitarian Interface: The Politics of Aid in Lebanon's Urban Peripheries,” examines humanitarian aid, transnational NGO governance, and the intersections of patronage, clientelism, and global aid systems in Lebanon. She is also a policy researcher specializing in Middle East politics. Her policy research focuses on hybrid armed actors, regional Shia politics, and social movements in Lebanon. Thanassis Cambanis is director of Century International.  Date: Tuesday, May 25, 2026 Episode: Order from Ashes 114

Cases of Ebola continue to rise in the eastern part of the Democratic Republic of Congo, with the number of suspected cases approaching 1,000, and suspected deaths at more than 200. Aid groups are warning they need more funding to tackle the disease, and health workers and volunteers are working to educate people and quash misinformation.

Welcome back to the Word on Fire Show. I'm Matthew Petrusek, senior director of the Word on Fire Institute and the host of the Word on Fire Show. Thank you for joining us. Although not widely reported in legacy media outlets, Christianity is, by far, the most persecuted religion in the world. From the Middle East and Africa to India, China, North Korea, and elsewhere, Christian communities regularly experience widespread humiliation, imprisonment, kidnappings, expulsions, and even murderous mob violence. While not as severe, Christians in parts of Europe and even right here at home, in the US, also often endure discrimination, exclusion, and ridicule. There is no ambiguity about who is carrying out these attacks or what motivates them. Like the martyrs of past centuries, millions of our Christian brothers and sisters are currently suffering because they profess faith in Jesus Christ. In response to this ongoing outrage, Bishop Robert Barron has released a new book called What Do Their Deaths Demand? Christian Persecution Today. Intended for widespread distribution, the book spotlights heartbreaking stories of the continued targeting of Christian communities throughout the world, offers a theological explanation for why Christianity has been under assault since its inception, and, most importantly, provides actionable ideas for what all of us can do to respond. Here to discuss the book—and why its message is more urgent than ever—is Bishop Robert Barron. Topics Covered 00:00 | Introduction 01:38 | The final meeting of the Religious Liberty Commission 02:51 | Why this book, and why now? 05:16 | Cardinal Pierbattista Pizzaballa's foreword 06:46 | Aid to the Church in Need 07:47 | Why Christian persecution is largely ignored 09:00 | Part 1: The Most Persecuted Religion 15:36 | Part 2: Why the Persecution of Christians? 22:41 | The fundamental quandary 25:09 | Part 3: So What Can We Do? 32:09 | Listener question: Should we present the crucifixion more positively? 34:38 | Join the Word on Fire Institute Links: Word on Fire Institute: https://institute.wordonfire.org/ NOTE: Do you like this podcast? Become a Word on Fire IGNITE member! Word on Fire is a non-profit ministry that depends on the support of our listeners . . . like you! So become a part of this mission and join IGNITE today to become a Word on Fire insider and receive some special donor gifts for your generosity.

Laura asks Miriam about Michael Egan's abuse of her brother and mother and Miriam shares how she broke through the terror and fear to hold Egan accountable for his cruel and sadistic abuse as well as the devastating long-term impact of life-changing trauma.   Listen as Laura identifies the patterns of behaviour, manipulation, coercive control, and missed opportunities to safeguard and protect. Together, Laura and Miriam explore: • Miriam's courageous fight for accountability and justice; • The lasting impact of coercive control and sadistic abuse; • The early warning signs and grooming behaviours; • The language and tactics used by coercive controllers; • How coercive control creates fear, silence, and compliance within families; • Why victims and survivors struggle to report abuse for years; • The importance of understanding patterns — not isolated incidents; • How systems can fail vulnerable children and survivors, and; • Reclaiming power, healing, and using lived experience to help others   Miriam also speaks about raising awareness and why she is undertaking a skydive to raise funds for Women's Aid to support women and children experiencing abuse. Please donate:https://www.justgiving.com/page/miriam-lake-1   TW: This episode is not an easy listen and includes discussions of sadistic cruelty and coercive control.  

Plus: Western Canadian Premiers meet in Alberta, Ontario patient tests negative for Ebola, Gaza activists return to Canada, White House shooting. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstory.bsky.social on Bluesky

As the Ebola outbreak in the Democratic Republic of Congo continues, the World Health Organisation has classified the regional risk as “very high”, while maintaining that the global risk remains low. Aid agencies say faith leaders are playing an important role in helping communities respond to the virus and challenge misinformation. William Crawley speaks to Poppy Anguandia, Country Director in the DRC for Tearfund, about the work being carried out with churches and mosques in affected areas.Two thousand ancient Jain manuscripts have been transferred to new custodians in the UK, in a move welcomed by members of the Jain community and scholars alike. The collection is expected to support preservation efforts and improve public and academic access to important religious texts.And a £48 million funding boost for heritage projects across the UK prompts fresh debate about how the nation preserves its religious and cultural history for future generations.Presenter: William Crawley Producers: Bara'atu Ibrahim & James Leesley Editor: Rajeev Gupta

Rich Embury is back again with another flashback to the ’70s, ’80s, and ’90s rock and metal scene! Rock History, and Classics from Savatage / W.A.S.P. / Lee Aaron / Flotsam and Jetsam / KISS (doubleshot) / Iced Earth / Europe / The Who / Rough Cutt / Hear ‘n Aid! This edition of Rich Embury's Power Hour aired initially LIVE on The Blitz 100.1 FM, KRFK Radio, Metal Crash Radio, Bulldogs Radio, Tripl3 Troubl3 Radio, Veckans Band Metal Radio, Rock On The Rise Radio, MetalRadioGR, NAR-Metal, Radio Infernale, Bloodstream Radio, Rock Nation, RockStar-Radio Underground, Earth Rock Radio, Whatever 68 Radio, KDUB Radio, CIA-Rock Radio, Rogue Rock Radio, Vibe Tunes Radio, Morning Wood Radio, Pirate Radio, Radio X (AU), Dark Haven Radio, Coming Home Well Radio (United By Service), Doc Rock's Metal Shop 101 Radio, CGCM Rock Radio, Stay Vintage Radio, RetroRock Radio, Northland Radio, Hard Rock Radio and Insane Realm Radio, Wednesday, May 20th, 2026. Secondary airings on Heavy Metal Radio, Digital Revolution Radio, Freekshow Radio, Ragebreed Radio, Metal World Web Radio, Radio Heavy Metal and more throughout the rest of the week. Savatage – Power of The Night W.A.S.P. – Wild Child Lee Aaron – I Like My Rock Hard Flotsam and Jetsam – Saturday Night’s Alright KISS – Tomorrow KISS – Domino Iced Earth – The Hunter Europe – The Final Countdown The Who – The Real Me Rough Cutt – Cutt Your Heart Out Hear ‘n Aid – Stars ——————————————————————————— SPONSORED BY FCK.FM MAGAZINE. A bi-monthly, FREE online magazine! Features rock & heavy metal, FCKgirls, gaming, horror, interviews, artist spotlights, and much more! Visit and share now: https://fck.fm/magazine ——————————————————————————— Also available to subscribe, download, and listen at the following major podcast sites & apps (and more):Apple Podcasts / Amazon Music / Audible / Mixcloud / iHeart Radio / TuneIn Radio / Player FM / Podchaser / Jiosaavn / Deezer / Podbean / Castbox / Radio Public / Pocket Cast / Podcast Addict / Castro / Overcast / Getme.radio / PodcastRepublic / Podcast.app / PodcastGuru / Pandora / Podcast Index Please leave a review on your favourite podcast site above.

Plus: NATO ministers meet in Sweden, Ebola outbreak update, 12 Canadian activists have arrived in Turkey after being deported from Israel, Stephen Colbert's farewell, and is Eurovision a good fit for Canada. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstory.bsky.social on Bluesky

Plus: Prime Minister Mark Carney condemns Israel's treatment of activists over an intercepted aid flotilla, generic versions of Ozempic are set to hit pharmacy shelves this week, Canada's first-ever PWHL championship goes to Montreal, and what's next for Tumbler Ridge? We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstory.bsky.social on Bluesky

Send us Fan MailIn this episode of the Blue Grit Podcast, we take on a growing problem in law enforcement: how quickly social media mobs form before the facts are known.Recent incidents in Galveston and Arp show exactly how dangerous that can be.In Galveston, an officer-involved shooting was quickly met with online outrage, but the facts matter. The suspect, Randy Martin, was recently released from prison after being convicted of murder. He was not pulled from the vehicle. He got out on his own, fought the officer, caused injuries, and grabbed the officer's weapon during the encounter. Aid was immediately rendered at the scene.In Arp, an officer investigating smoke and flames inside city limits was aggressively approached by dogs that came through a fence line. The landowner later admitted, “Everyone knows my dogs bite.” Instead of accountability, the officer, department, and chief became targets of online attacks and threats.Joining this episode are TMPA Executive Director Kevin Lawrence, Field Representative Leighton Guarnere, Regional Attorney Amanda Bolin, and Galveston Municipal Police Association President Anthony Rogers.Together, they break down how false narratives spread, how officers become targets before investigations are complete, and why associations must respond quickly, aggressively, and factually when members are under attack.The message is simple:Let the evidence come out. Let the investigation happen. Let the facts lead.But stop allowing social media mobs to convict officers for doing their jobs.Support the showemail us at- bluegrit@tmpa.org

A coercive control law can be groundbreaking and still leave survivors asking, “Why doesn't life feel safer?”David and Ruth are joined by Dr. Marsha Scott, CEO of Scottish Women's Aid, to talk about Scotland's hard-won reforms and the uncomfortable truth behind them: Legal change is only the beginning, and implementation is where domestic abuse reform succeeds or fails. They dig into what makes Scotland's coercive control framework so influential, including its course of conduct focus and why impact matters more than trying to read a perpetrator's “intent.” Dr. Scott shares what the law has changed in public understanding and what has not changed yet in courts, sentencing, and survivor trust. Ruth, David, and Dr. Scott also get practical about what closes the implementation gap: infrastructure, better evidence, skilled supervision, and real accountability when systems keep defaulting to old habits. Then they turn to family court, child protection, and child contact decision-making, where children's rights can get lost and where poor documentation can make the perpetrator disappear while the survivor is judged through a deficit lens. They talk about reports, mental health models, and what it takes to pivot practice toward perpetrator patterns as parenting behaviours with measurable harm to kids. If you care about coercive control, children's safety, and systems change that actually sticks, hit subscribe, share the episode with a colleague, and leave us a review on your favorite podcast platform.Send us Fan Mail Now available! Mapping the Perpetrator's Pattern: A Practitioner's Tool for Improving Assessment, Intervention, and Outcomes The web-based Perpetrator Pattern Mapping Tool is a virtual practice tool for improving assessment, intervention, and outcomes through a perpetrator pattern-based approach. The tool allows practitioners to apply the Model's critical concepts and principles to their current case load in realCheck out David Mandel's new book Stop Blaming Mothers and Ignoring Fathers: How to Transform the Way We Keep Children Safe from Domestic Violence.Visit the Safe & Together Institute website.Start taking Safe & Together Institute courses. Check out Safe & Together Institute upcoming events.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Miriam Lake was terrorized as a little girl by Michael Egan, a coercive controller who groomed the family through charm and love bombing before subjecting Miriam, her siblings, and mother to years of sadistic abuse. Listen as Laura identifies the patterns of behaviour and missed opportunities to safeguard and protect. Together, Laura and Miriam explore: The early warning signs and grooming behaviours  The language of coercive control How coercive control creates fear, silence, and compliance within families  Why victims and survivors struggle to report abuse for years  The importance of understanding patterns -not isolated incidents  How systems can fail vulnerable children and survivors    Miriam also speaks about reclaiming her power, raising awareness, and why she is now undertaking a skydive to raise funds for Women's Aid and support other women and children experiencing abuse. Please donate:https://www.justgiving.com/page/miriam-lake-1   TW: This episode is not an easy listen and you will hear details about sadistic and cruel abuse.   

Between 1918 and 1921, over a hundred thousand Jews were murdered in Ukraine by peasants, townsmen, and soldiers who blamed the Jews for the turmoil of the Russian Revolution. In hundreds of separate incidents, ordinary people robbed their Jewish neighbors with impunity, burned down their houses, ripped apart their Torah scrolls, sexually assaulted them, and killed them. Largely forgotten today, these pogroms—ethnic riots—dominated headlines and international affairs in their time. Aid workers warned that six million Jews were in danger of complete extermination. Twenty years later, these dire predictions would come true. Jeffrey Veidlinger's new book In the Midst of Civilized Europe: The Pogroms of 1918-1921 and the Onset of the Holocaust draws upon long-neglected archival materials, including thousands of newly discovered witness testimonies, trial records, and official orders, showing for the first time how this wave of genocidal violence created the conditions for the Holocaust. Join us for a discussion on this important new book featuring Jeffrey Veidlinger in conversation with Steven Zipperstein. This book talk originally took place on November 30, 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Between 1918 and 1921, over a hundred thousand Jews were murdered in Ukraine by peasants, townsmen, and soldiers who blamed the Jews for the turmoil of the Russian Revolution. In hundreds of separate incidents, ordinary people robbed their Jewish neighbors with impunity, burned down their houses, ripped apart their Torah scrolls, sexually assaulted them, and killed them. Largely forgotten today, these pogroms—ethnic riots—dominated headlines and international affairs in their time. Aid workers warned that six million Jews were in danger of complete extermination. Twenty years later, these dire predictions would come true. Jeffrey Veidlinger's new book In the Midst of Civilized Europe: The Pogroms of 1918-1921 and the Onset of the Holocaust draws upon long-neglected archival materials, including thousands of newly discovered witness testimonies, trial records, and official orders, showing for the first time how this wave of genocidal violence created the conditions for the Holocaust. Join us for a discussion on this important new book featuring Jeffrey Veidlinger in conversation with Steven Zipperstein. This book talk originally took place on November 30, 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/jewish-studies

Between 1918 and 1921, over a hundred thousand Jews were murdered in Ukraine by peasants, townsmen, and soldiers who blamed the Jews for the turmoil of the Russian Revolution. In hundreds of separate incidents, ordinary people robbed their Jewish neighbors with impunity, burned down their houses, ripped apart their Torah scrolls, sexually assaulted them, and killed them. Largely forgotten today, these pogroms—ethnic riots—dominated headlines and international affairs in their time. Aid workers warned that six million Jews were in danger of complete extermination. Twenty years later, these dire predictions would come true. Jeffrey Veidlinger's new book In the Midst of Civilized Europe: The Pogroms of 1918-1921 and the Onset of the Holocaust draws upon long-neglected archival materials, including thousands of newly discovered witness testimonies, trial records, and official orders, showing for the first time how this wave of genocidal violence created the conditions for the Holocaust. Join us for a discussion on this important new book featuring Jeffrey Veidlinger in conversation with Steven Zipperstein. This book talk originally took place on November 30, 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/eastern-european-studies

How Xi Handled the Barbarian Who Went Home Emptyhanded Ready to Sell Out Taiwan | The US Offers $100 Million in Aid to Cubans Suffering Collective Punishment As They Run Out of Oil From a Total US Blockade | Republicans Fight Against Imaginary Problems Like Cultural Marxism Because They Have Nothing Real to Offer backgroundbriefing.org/donate twitter.com/ianmastersmedia bsky.app/profile/ianmastersmedia.bsky.social linktr.ee/backgroundbriefing

Women are being forced to turn to loan sharks due to a "hidden" but devastating form of economic abuse, according to new research. Scottish Women's Aid has published a study on the problem of coerced debt – where an abusive current or ex-partner builds up debt in their victim's name, either without consent or knowledge or through force, threat or coercion. Anita Rani is joined by Dr Jenn Glinski, author of the report and the national policy lead for economic abuse at Scottish Women's Aid, to talk about the report findings.Menopause can be challenging for many women, but for those with ADHD, the experience can often feel like life is completely unravelling. For some women in their 40s, 50s and 60s it can also be the first time they realise they may have ADHD, as fluctuating hormones amplify their challenges with sleep, mood, attention and overwhelm. GP and Menopause expert Dr Helen Wall joined Anita to talk about her new book Menopause and ADHD, which aims to debunk some of the myths and support women navigating the combination.A new medical device to assist at birth is now in use in eight NHS trusts in the UK and 40 hospitals in the whole of Europe. The OdonAssist can replace forceps in many situations and is a much gentler way to deliver a baby which is stuck in the birth canal. NHS Specialist registrar Dr Emily Hotton has worked on the UK clinical trials. She describes how the device works and why it can give a much better outcome for both mothers and babies.M&S has announced that following a successful trial they are ditching the measuring tape for bra fittings. Other underwear retailers have done this for years, but how does it work fitting a bra by eye? Joanna Wakefield-Scurr, Professor of Biomechanics at Portsmouth University, and virtual bra fitter Katie Weir join Nuala McGovern to discuss. Canwen Xu was born in China and moved to the US when she was two years old. She grew up in predominately white areas – North and South Dakota and Idaho. When she was 18 she gave a TEDx talk, titled, I Am Not Your Asian Stereotype, which has been watched more than 3.7 million times. Canwen joins Anita to discuss her debut novel - Boring Asian Female – and its themes of identity, ambition, failure, and obsession.Love it or dread it, flat-pack furniture tests us all. But for Hayley McAuley from Wigan, it's a sport - she's just defended her title as Flatpack World Champion and tells Anita about the win.Presenter: Anita Rani Producer: Dianne McGregor

This week we speak with author Jeff Lockert and learn great leadership qualities from the greatest of leaders. We find out the results of the Religious Freedom report from Aid to the Church in Need, and we meet hip hop singer/songwriter Carlos Zamora, aka C2six.

Women are being forced to turn to loan sharks due to a "hidden" but devastating form of economic abuse, according to new research. Scottish Women's Aid has published a study on the problem of coerced debt – where an abusive current or ex-partner builds up debt in their victim's name, either without consent or knowledge or through force, threat or coercion. Anita Rani is joined by Dr Jenn Glinski, author of the report and the national policy lead for economic abuse at Scottish Women's Aid, to talk about the report findings.Canwen Xu was born in China and moved to the US when she was two years old. She grew up in predominately white areas – North and South Dakota and Idaho. When she was 18 she gave a TEDx talk, titled, I Am Not Your Asian Stereotype, which has been watched more than 3.7 million times. Canwen joins Anita to discuss her debut novel - Boring Asian Female – and its themes of identity, ambition, failure, and obsession.The Government is consulting on an outright ban of social media for under-16s, as well as other measures designed to stop teenagers accessing addictive and harmful material. In March in the US, a Los Angeles jury handed down an unprecedented win for a young woman who had sued Meta and Google over her childhood addiction to social media. So, what is social media addiction and how do you identify it in children? What's the tipping point between a ‘keen interest' and an addiction? Anita is joined by Dr Bernadka Dubicka, a consultant child and adolescent psychiatrist, and Jenny Afia, a privacy and reputation lawyer for the law firm Schillings, who contributed to the UK Children's Commissioner's Digital Task Force.The Royal Shakespeare Company's musical production of The Boy Who Harnessed the Wind has just transferred to London's West End. Based on the true story of 13-year-old William Kamkwamba who, in drought-stricken Malawi, and despite the lack of support from those around him, dreamt of saving his village. Anita is joined by the director Lynette Linton, and Madeleine Appiah, who plays William's mother.Presenter: Anita Rani Producer: Rebecca Myatt

From MPR News, Art Hounds are members of the Minnesota arts community who look beyond their own work to highlight what's exciting in local art. Their recommendations are lightly edited from the audio heard in the player above.Want to be an Art Hound? Submit here.Alight-a-WhirlIt's Art-a-Whirl weekend! The Northeast Minneapolis Arts Association (NEMAA) puts on the annual celebration of all things local art, with three days of open studios, live events, music and food vendors. Hours are Friday 5-8 p.m., Saturday 12–8 p.m. and Sunday 12–5 p.m.It's a favorite event for Molly Reopelle, a muralist who works under the name “Made by Molly Jo.” One space she's particularly looking forward to seeing is Alight-a-Whirl, an annual art sale fundraiser for Alight. The nonprofit supports displaced people and refugees in the U.S. and across the world.Alight-a-Whirl features a 500-piece art sale with work by local, international and refugee artists, as well as pop-up events, including a Friday happy hour and portrait painting. All profits from the art sale support Alight.Molly says: One of the people I'll be looking at [at Alight-a-Whirl] is Lora Hlavsa. She might be recognizable because she developed the artwork with NEMAA for the Art-a-Whirl branding this year, and she's got a really cool new series called The People's Pantry, which is using really familiar objects like foods and pantry staples to explore some of her lived experience and then reflect on migration and cultural access.— Molly ReopelleGender Joy Art ShowJenn Watters in Duluth recommends seeing the annual Gender Joy Art Show, whose creative works are expressions of joy made by female and gender expansive people of all ages. The exhibit is put on this year by the YWCA of Duluth and the Program for Aid to Victims of Sexual Assault (PAVSA), and the show will include work created by PAVSA's weekly art group. New this year is an interactive art exhibit entitled “The Elephant in the Room,” hosted by Rachel Gilbertson of Art of Presence. Visitors to the exhibit are encouraged to write words or phrases they've received that were harmful to their gender identity, which Gilbertson will transform into a brightly colored work with an elephant's face emerging from the chaos. The exhibition runs until June 27 in the Atrium of Zeitgeist in Duluth.Watters who particularly enjoys seeing the work created by children.Jenn says: This is one of my favorite art shows each year.— Jenn WattersOne Subject PressDeborah Keenan, a Twin Cities poet and former longtime teacher at Hamline's MFA program, is trumpeting the work of former student Zach Czaia, who runs One Subject Press. A year ago, Czaia bought a Chicago-based press and moved it to Minneapolis, through which he publishes a wide range of work from poetry to fiction to theology. On Friday, May 15, the press will celebrate its one-year anniversary with an evening of literary readings and food. Czaia will read, along with poets Greg Watson and Suzanne Swanson, and attendees are invited to bring a poem to share. The event runs from 6-8 p.m. at Inkwell Booksellers in northeast Minneapolis. It is open to the public, though registration is requested through the press.Deborah says: It's called One Subject Press after a Richard Rodriguez quote: “There is only one subject: what it feels like to be alive. Nothing is irrelevant. Nothing is typical.” That's the flag Zach carries into battle, and it's a great flag.I think lots of people who love poetry and essays should absolutely show up [to this event.]— Deborah Keenan

Harry speaks with Brandon Scott of Aid to the Church in Need [ACN] Ireland about the state of Christianity in the Middle East, where Christian populations in Syria and Iraq have fallen by 80% over 20 years, and where 500 Catholics in Gaza are living at the epicentre of ongoing conflict. Brandon describes ACN's work: […] L'articolo Catholics in Gaza, Syria and Iraq – Brandon Scott from Aid to the Church in Need [ACN] proviene da Radio Maria.

It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more.  Announcing Community Commericals! Learn how to get your message on the show here. Don't miss our in-person events: www.diabetes-connections.com/events  Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/   XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community.  It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting?autologincheck=redirected   XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada ‌​has approved the first generic ​version of ​Danish ⁠drugmaker ⁠Novo ‌Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. https://www.cbc.ca/news/health/ozempic-generic-health-canada-9.7180566 XX  Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D  The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028.   XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage.   Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. https://www.msn.com/en-us/money/companies/insulet-recalling-certain-defective-omnipod-insulin-delivery-devices/ar-AA1YyslT?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company's Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it's the episode just before this one. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pumps-over-software-malfunction/818260/   XX Switching CGMs didn't make a measurable difference for adults using MiniMed's pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. "When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more," Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. "Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want." I'm including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery   XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. "More research is needed to see if there are other factors that are associated with risk reduction." https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants   XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world's first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study.   The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can't necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison.   The Virginia senator wrote on the social platform X, "As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we've received. Thank you to everyone for your kind words." Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were "heartbroken beyond words" by their daughter's passing.   On Monday, the former Virginia governor said his daughter "was a deeply empathetic and engaged person" and that "as recently as the day she passed, she was full of ideas and suggestions" for him, including how he could improve his social media presence.   "She used to say to me: 'Dad, you have the power — you have to use it.' She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways," he added.       "If I can find any solace during this time, it's that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy's name."   Warner concluded, "I look forward to returning to the Senate this week and continuing that essential work."   Madison Warner is survived by two younger sisters.     An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC's National Diabetes Statistics Report.   An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes.   Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D.  The Halo Awards recognize the most outstanding corporate social impact efforts over the past year.

1. Secret Service Funding & Political Conflict The U.S. Secret Service stopped an alleged assassination attempt and they were underfunded due to Department of Homeland Security budget disputes. Democrats repeatedly voted against DHS/Secret Service funding, framing this as irresponsible given security risks. This political rhetoric contributes to political violence. Discusses legal opposition to construction of a White House ballroom with enhanced security features. The court’s temporary halt to construction is portrayed as dismissive of national security concerns. There are repeated threats against President Trump as justification for heightened security. 3. Radicalization & Political Violence Narrative Attributes recent acts of political violence to left‑wing ideology and alleged “Marxist” indoctrination in academia. Cites a purported manifesto to argue that ideological framing of “oppressors vs. victims” is used to justify violence. 4. FBI Raids and Minnesota Fraud Allegations FBI raids on over 20 childcare and nonprofit facilities in Minneapolis related to alleged large‑scale fraud. The fraud is involving misuse of taxpayer funds, particularly in programs tied to childcare and social services. Minnesota political leaders are accused of ignoring or covering up fraud while later taking credit for enforcement. There is widespread abuse of SNAP (food stamp) benefits, including recipients allegedly owning high‑end luxury vehicles. The federal eligibility rules (broad‑based categorical eligibility) are at fault for enabling fraud. Both fraudsters and policymakers who support current rules should be held accountable. Democratic officials are benefiting politically from fraud & welfare expansion. Specific figures are cited as symbols of incompetence, corruption, or ideological extremism. 7. DEI Policies & Homelessness Programs Describes homelessness assistance systems, particularly in Portland, Oregon, as driven by DEI (Diversity, Equity, Inclusion) scoring systems. Aid is prioritized based on race, sexuality, or identity over economic need leads to ineffective outcomes. Despite very high spending per homeless individual, homelessness‑related deaths increased significantly. Please Hit Subscribe to this podcast Right Now. Also Please Subscribe to the 47 Morning Update with Ben Ferguson and The Ben Ferguson Show Podcast Wherever You get You're Podcasts. And don't forget to follow the show on Social Media so you never miss a moment! Thanks for Listening YouTube: https://www.youtube.com/@VerdictwithTedCruz/ Facebook: https://www.facebook.com/verdictwithtedcruz X: https://x.com/tedcruz X: https://x.com/benfergusonshowYouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

According to the latest Department of Education data, more than 7000 children under six were suspended in the 24 /25 school year in England and the number of children losing learning to repeat suspensions has doubled in two years, with the steepest rises among the youngest. This is against a slowing of suspensions in secondary schools. So why is this happening in primary schools? Anita Rani is joined by Kiran Gill, chief executive of The Difference, a school leadership charity who's been analysing this data.Last month eleven year old Bodhana Sivanandan became England's highest ranked female chess player. The numbers of women registering to compete is slowly rising, but the game is still male dominated. Anita talks to two women who work in chess to find out more - Sarah Longson, CEO of the UK chess challenge, and chess player and streamer Sarah El Barbry.Last October a Sikh woman was subjected to racially aggravated rape and assault in her own home just outside Birmingham. Perpetrator John Ashby followed his victim - a stranger to him - off a bus into her house, where he carried out the brutal assault. Last week he was sentenced to life in prison. The BBC's Midlands Correspondent Phil Mackie joins Anita to tell us more about the case, alongside Sukhvinder Kaur, the Chair of Trustees at Sikh Women's Aid.As the spring dawn chorus reaches its peak, a new book is challenging long held assumptions about birdsong, and revealing the overlooked role of female birds. Researcher Lucy McRobert, collaborator for the new book, The Sound of Birding: Second Edition, joins Anita to tune our ears to a richer, more complex soundscape. Pippa Cleary is the only female British composer to have had three musicals in the West End, with hits like The Secret Diary of Adrian Mole and The Great British Bake Off Musical. Her latest show, Bank of Dave the Musical, co-written with Rob Madge, is about to make its world premiere and she joins Anita to talk about turning the true life story of Dave Fishwick into a joyful stage show.Presenter: Anita Rani Producer: Corinna Jones

On this episode of the Hayek Program Podcast, Peter Boettke talks with Bill Easterly about his new book, Violent Saviors: The West's Conquest of the Rest. Drawing on figures such as Adam Smith, P.T. Bauer, and Amartya Sen, Easterly argues that material progress alone cannot justify the denial of human dignity and consent. The conversation explores the idea of the “benevolent autocrat” and examines how both colonialism and modern development policy have too often treated people as objects of improvement rather than agents of their own lives. Along the way, Boettke and Easterly discuss state capacity, slavery, colonialism, migration, and post-communist transitions, making the case that freedom is not just a means to development but an end in itself.Dr. William Easterly is Professor Emeritus of Economics at New York University and Co-director Emeritus of the NYU Development Research Institute. He is the author of numerous books, including The Tyranny of Experts: Economists, Dictators, and the Forgotten Rights of the Poor (Basic Books, 2014), The White Man's Burden: Why the West's Efforts to Aid the Rest Have Done So Much Ill and So Little Good (Penguin Books, 2006), and The Elusive Quest for Growth: Economists' Adventures and Misadventures in the Tropics (MIT Press, 2001).**This episode was recorded on February 2, 2026**Show Notes:Acemoglu and Robinson, The Narrow Corridor: States, Societies, and the Fate of Liberty (Penguin Books, 2020)Amartya Sen, Development As Freedom (Vintage, 2000)David Colander, Why aren't Economists as Important as Garbagemen? (Routledge, 1991)Matt Kibbe, Don't Hurt People and Don't Take Their Stuff: A Libertarian Manifesto (HarperCollins, 2015)If you like the show, please subscribe, leave a 5-star review, and tell others about the show! We're available on Apple Podcasts, Spotify, Amazon Music, and wherever you get your podcasts.Check out our other podcast from the Hayek Program! Virtual Sentiments is a podcast in which political theorist Kristen Collins interviews scholars and practitioners grappling with pressing problems in political economy with an eye to the past. Subscribe today!Follow the Hayek Program on Twitter: @HayekProgramFollow the Mercatus Center on Twitter: @mercatusCC Music: Twisterium

Ouch! You've just gotten a paper cut on your finger. What's the first thing you do? If you're like most people, you'll probably put your finger in your mouth. If you think about it, you probably have no idea why you put your finger into your mouth. Actually, when a dog licks its wounds or when you put your paper cut-ravaged finger in your mouth, you are beginning medical treatment.Medical science is only just learning what God knew when He built this reaction into us. The saliva of mammals and human beings contains Epidermal growth factor. Studies show that when epidermal growth factor is applied to wounds, healing takes place much faster. Epidermal growth factor increases the number of cells available to grow new skin over a wound. It also encourages capillaries to form near the wound to increase blood supply. Epidermal growth factor doubles the amount of new DNA at the wound site. Finally, it increases the amount of collagen in the wound to give the new tissue the strength to close up and remain closed.Researchers have little idea how epidermal growth factor works. They are still researching this powerful medicine that's found in our saliva.Only our wise and loving Creator could have provided us with this convenient and powerful medical treatment. Only He could have built into us the natural reaction of putting an injured finger into our mouth. Like so much else in the creation, this blessing is too well designed to be nothing more than a series of unrelated coincidences.Nehemiah 9:6“Thou, even thou, art Lord alone; thou hast made heaven, the heaven of heavens, with all their host, the earth, and all things that are therein, the seas, and all that is therein, and thou preservest them all; and the host of heaven worshippeth thee.”Prayer: Dear Father, our pagan world talks about chance and coincidence. But I learn in Your Word that there is no such thing. Cleanse my thinking and speech of this pagan influence so that I may better witness Your truth. In Jesus' Name. Amen.REF.: "An Aid to Healing that Simply Can't be Licked." Discover. To support this ministry financially, visit: https://www.oneplace.com/donate/1232/29?v=20251111

598,135 views  Streamed live on Apr 20, 2026  #Bonya #MiddleEast #TCK#Arestovich #Shelest #War #Trump #IranFundraising for a vehicle to support the logistical needs of the 5th Company, 420th Separate Battalion of Unmanned Systems.

We mark this moment in both Gaza and Israel. In Gaza, it has been six months since major hostilities with Israel ended. Aid for the territory's two million residents has resumed but it isn't sufficient and reconstruction has yet to begin. We hear from some residents about their lives today.And Israel celebrates its Independence Day during a rare pause in three conflicts: Gaza, Iran and Lebanon. It is the Gaza war that is the major theme for the country's official celebration.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

It's Monday and Lauretta has as her guest, AnnMarie Miller of the organization Aid for Women. Lauretta leads a discussion with AnnMarie as she talks about the organization.  AnnMarie share the programs and services available to women through their organization.  AnnMarie discusses how they help inform and support women, offering assistance so that the women can make the choices best suited for themselves. The programs are free to all.  While the programs and services are free, the organization does seek donations and benefactors as they are a non-profit and are therefore fully funded by donations and grant money. To learn more about their services or to solicit assistance or get involved please visit their website at helpaidforwomen.org. Or call 312-621-1100. St. Stanislaus Kostka Parish  helpaidforwomen.org

The music in this broadcast has been removed from this podcast for rights reasons. The Secretary of State for Northern Ireland said last week that it is "shameful" that Northern Ireland is the part of the UK where it is "most dangerous to be a woman". He described the scale of violence against women and girls in the area as a "source of enormous sadness" and "shame". Thirty women have been violently killed in Northern Ireland since 2020, two lost their lives just this month. They were 28-year-old Amy Doherty and 23-year-old Ellie Flanagan. So what is being done about the violence, which is predominantly carried out by men? Krupa Padhy is joined by Allison Morris from the Belfast Telegraph, BBC journalist Jennifer O'Leary, who has made a documentary telling the story of domestic violence in Northern Ireland through the tale of a women's refuge, as well as Marie Brown, CEO of Foyle Women's Aid and Foyle Family Justice Centre. Rita Wilson discusses her new album of deeply personal songs, Sound of a Woman. She's a film and TV actor, as well as a singer/songwriter, and was the producer behind blockbuster movies Mamma Mia! and My Big Fat Greek Wedding. Rita also happens to be married to Tom Hanks. She joins Krupa to share her reflections on marriage, parenthood and illness. The Society of Radiographers has said that the demand for ultrasound has increased, but there aren't enough people being trained to do the work. They say this is leading to pregnant women and cancer patients facing delays for vital ultrasound scans which could be 'dangerous for the patient.' Rachel Nolan, president elect of the Society of Radiographers, tells us what needs to change.A recent Vogue Business size inclusivity report has documented a decline in the use of models with bigger bodies on the catwalk. Of the almost 8,000 looks presented across over 180 shows and presentations for Autumn/Winter 2026, over 97% of the looks were what is called "straight-size" (that's a UK size 4-8), just over 2% were mid-size (a UK size 10 - 16), and only 0.3% were plus-size (a UK size 18). Last season, it was 0.9%. So plus-size representation has declined. The report also cites the growing use of weight loss drugs (GLP-1s) as a key part of the change compared to recent years. So, what's happening in the fashion industry when it comes to body-size inclusivity, and are we seeing an impact on the clothing sizes available in the shops on our high streets? Elizabeth Paton, Fashion Editor of the Financial Times, and Gabriele Dirvanauskas, Deputy Editor at Drapers magazine, join Krupa in the studio.

It's Monday, March 30th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Adam McManus Nigerian archbishop to Trump:  “Give us weapons” to “eradicate” Islamic terrorists Archbishop Ignatius Kaigama of Abuja, Nigeria called on the Trump administration to provide intelligence and weapons to the Nigerian government to help combat the brutal persecution of the country's Christians at the hands of Islamic terrorists, reports LifeSiteNews.com. During a March 20th press briefing hosted by Aid to the Church in Need as, Archbishop Kaigama praised Trump for being the first world leader to “clearly and unequivocally” declare that Nigerian Christians are being persecuted, reports EWTN. The archbishop emphasized, however, that Trump's remarks and his administration's December bombing in Nigeria have only emboldened Islamist terror groups, such as Boko Haram, to carry out more attacks on Christians. He called on the 47th president to share intelligence with and provide weapons to the Nigerian government to help them put an end to the persecution for good. Kaigama said, “I was glad when I heard Donald Trump say, ‘We are going to go to Nigeria; we are going to put an end to Boko Haram. At Christmas, we received a gift — a bomb that fell on Nigerian soil — and, truth be told, I could not say whether it did any good. “That incident, coupled with Donald Trump's words, has greatly inflamed the passions of the Islamists in that territory. The number of attacks, the number of kidnappings carried out by Boko Haram and other groups, has been rising ever since.” Islamic persecution of Christians in Nigeria tied to sharia law Persecution of Christians in Nigeria began to spike after 1999, when 12 northern states adopted Sharia law. The rise of the terrorist group Boko Haram in 2009 marked a dramatic escalation in the attacks. Famously, the group kidnapped hundreds of schoolgirls in 2014; 87 of them are still listed as “missing.” From 2009 to 2022, over 50,000 Christians were killed in the country. A 2024 report found that more than 8,000 Nigerian Christians were killed and thousands more were abducted in 2023 alone, making it the bloodiest year on record for Islamic attacks against Christians in the country. Sportscaster Stephen Smith calls out hypocritical Democrats Stephen A. Smith, the ESPN sportscaster, speaks the truth when he ventures into the political world. This time, he chastised Democrats for hypocritically complaining about President Donald Trump's willingness to do something about the growing Iranian threat. Listen. SMITH: “You got a lot of nerve to be in the face of the American people saying for numerous administration, ‘Iran is a problem. They have to be dealt with.'  And then this man deals with them, and then all of a sudden, you complaining about him now. It doesn't really make sense. It's a lack of consistency.” BILL CLINTON: “I am formally announcing my intention to cut off all trade and investment with Iran.” GEORGE W. BUSH: “Our second goal is to prevent regimes that sponsored terror from threatening America or our friends and allies.  Iran aggressively pursues these weapons and exports terror while an unelected few repress the Iranian people's hope for freedom.” BARACK OBAMA: “I strongly believe that our national security interest now depends upon preventing Iran from obtaining a nuclear weapon.” JOE BIDEN: “Well, I can say to you, Iran will never get a nuclear weapon on my watch, as they say.” DONALD TRUMP:  “As President of the United States, I would never allow the world's number one state sponsor of terror to obtain a nuclear weapon. I said that for a long time, and I didn't.” 3,500 U.S. Troops arrive in Middle East as Iran war strikes intensify More than 3,500 U.S. troops, including the U.S.S. Tripoli with about 2,500 Marines, arrived in the Middle East, officials announced Saturday, as strikes in the Iran war intensified, reports CBS News. It's the most updated of the amphibious warships, known as a "big deck," which allows more room for F-35 Stealth Fighter Jets, Ospreys and other aircraft. The ship had previously been based in Japan when the order to deploy to the Middle East came almost two weeks ago. Corey Lewandowski out at Department of Homeland Security Corey Lewandowski, a special government employee who served as a top adviser to former Homeland Security Secretary Kristi Noem, no longer has a role with the DHS, reports NewsNation.com. Last week, Democrats on the House Oversight Committee called for an investigation, saying that almost immediately after entering the agency, Lewandowski “exercised outsized influence over DHS far beyond what a special government employee is authorized to do.” Lewandowski was the campaign manager for President Trump in 2016. Plus, according to the September 2021 report of conservative media outlet American Greatness, he had an extramarital affair with the married South Dakota governor Kristi Noem, for whom he had long been a political advisor. Exodus 20:14 says, “You shall not commit adultery.” War Secretary Pete Hegseth reforms Chaplain Corps War Secretary Pete Hegseth says his latest reforms will allow the Chaplain Corps to fulfill its mission of being the spiritual backbone of America's military, reports The Western Journal. HEGSETH: “In previous administrations, our Chaplain Corps was infected by political correctness and secular humanism. The core functions of the Chaplain Corps were changed and watered down until they were viewed by many as nothing more than therapists. Faith and virtue were traded for self-help and self-care. “The crucible of combat tests more than the body. It tests conviction, character and spirit. The military's Chaplain Corps serves as spiritual and moral backbone of our nation's armed forces. Chaplains help forge spiritual readiness across the force, and that matters because in combat, in crisis, and in loss, a war fighter needs more than a coping mechanism. “They need truth, ‘big T' truth. They need conviction. They need a shepherd. Spiritual health is equally important to a service member's physical and emotional health.” According to a War Department news release, the number of faith codes used in the service has been winnowed down to 31. In 2017, the Pentagon issued a list of 221 groups that qualified as a religious group. Oddly enough, the list included witches and atheists, according to Stars and Stripes. Hegseth said, “It was impractical and unusable, and many codes were never used at all.” He noted that 82% of service members, who identify as being religious, used six of the codes. The War Secretary added that the chaplains will display their religious insignia on their uniforms instead of their ranks. He said, “A chaplain is first and foremost a chaplain, and an officer second. This change is a visual representation of that fact.” Christian stewardess gave her life for passengers on sinking ship And finally, on March 30th, 1899, the steamship Stella, carrying 147 passengers and 43 crew. struck some rocks in a fog while sailing to Guernsey, the second largest island in the Channel Islands in the English Channel. Mary Rogers, a cheerful, kind, and hard-working stewardess, supervised the escape of a large number of women and relinquished her own life vest to the last of them and gave up her place in the lifeboat. Four lifeboats were successfully launched and one capsized. Raising her hands to Heaven, Mary Rogers yelled, “Lord, have me!” as the ship sank beneath her within eight minutes. John 15:13 says, “Greater love has no one than this: to lay down one's life for one's friends.” Or, in this case, absolute strangers. Close And that's The Worldview on this Monday, March 30th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.